Literature DB >> 36266294

Biallelic variants in coenzyme Q10 biosynthesis pathway genes cause a retinitis pigmentosa phenotype.

Neringa Jurkute1,2, Francesca Cancellieri3,4, Lisa Pohl5, Catherina H Z Li6,7, Robert A Heaton8, Janine Reurink6,9, James Bellingham10, Mathieu Quinodoz3,4,11, Georgia Yioti12, Maria Stefaniotou12, Marianna Weener13, Theresia Zuleger14, Tobias B Haack14,15, Katarina Stingl5,15, Carel B Hoyng6,7, Omar A Mahroo16,10, Iain Hargreaves8, F Lucy Raymond17,18, Michel Michaelides16,10, Carlo Rivolta3,4,11, Susanne Kohl19, Susanne Roosing6,9, Andrew R Webster16,10, Gavin Arno20,21,22.   

Abstract

The aim of this study was to investigate coenzyme Q10 (CoQ10) biosynthesis pathway defects in inherited retinal dystrophy. Individuals affected by inherited retinal dystrophy (IRD) underwent exome or genome sequencing for molecular diagnosis of their condition. Following negative IRD gene panel analysis, patients carrying biallelic variants in CoQ10 biosynthesis pathway genes were identified. Clinical data were collected from the medical records. Haplotypes harbouring the same missense variant were characterised from family genome sequencing (GS) data and direct Sanger sequencing. Candidate splice variants were characterised using Oxford Nanopore Technologies single molecule sequencing. The CoQ10 status of the human plasma was determined in some of the study patients. 13 individuals from 12 unrelated families harboured candidate pathogenic genotypes in the genes: PDSS1, COQ2, COQ4 and COQ5. The PDSS1 variant c.589 A > G was identified in three affected individuals from three unrelated families on a possible ancestral haplotype. Three variants (PDSS1 c.468-25 A > G, PDSS1 c.722-2 A > G, COQ5 c.682-7 T > G) were shown to lead to cryptic splicing. 6 affected individuals were diagnosed with non-syndromic retinitis pigmentosa and 7 had additional clinical findings. This study provides evidence of CoQ10 biosynthesis pathway gene defects leading to non-syndromic retinitis pigmentosa in some cases. Intronic variants outside of the canonical splice-sites represent an important cause of disease. RT-PCR nanopore sequencing is effective in characterising these splice defects.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 36266294      PMCID: PMC9581764          DOI: 10.1038/s41525-022-00330-z

Source DB:  PubMed          Journal:  NPJ Genom Med        ISSN: 2056-7944            Impact factor:   6.083


  41 in total

1.  Determination of coenzyme Q10 status in blood mononuclear cells, skeletal muscle, and plasma by HPLC with di-propoxy-coenzyme Q10 as an internal standard.

Authors:  Andrew J Duncan; Simon J R Heales; Kevin Mills; Simon Eaton; John M Land; Iain P Hargreaves
Journal:  Clin Chem       Date:  2005-12       Impact factor: 8.327

2.  The COQ2 genotype predicts the severity of coenzyme Q10 deficiency.

Authors:  Maria Andrea Desbats; Valeria Morbidoni; Micol Silic-Benussi; Mara Doimo; Vincenzo Ciminale; Matteo Cassina; Sabrina Sacconi; Michio Hirano; Giuseppe Basso; Fabien Pierrel; Placido Navas; Leonardo Salviati; Eva Trevisson
Journal:  Hum Mol Genet       Date:  2016-08-04       Impact factor: 6.150

3.  Encephalopathy, kidney failure and retinopathy. CoQ10 deficiency due to COQ8B mutation.

Authors:  Victor Adam Lancet; Yolanda Romero Salas; María Luisa Justa Roldán; María Concepción García Jiménez; Gema Ariceta Iraola
Journal:  An Pediatr (Engl Ed)       Date:  2021-04-27

4.  Diffuse mesangial sclerosis in a PDSS2 mutation-induced coenzyme Q10 deficiency.

Authors:  Béla Iványi; Gábor Z Rácz; Péter Gál; Kitti Brinyiczki; István Bódi; Tibor Kalmár; Zoltán Maróti; Csaba Bereczki
Journal:  Pediatr Nephrol       Date:  2017-10-14       Impact factor: 3.714

5.  A novel inborn error of the coenzyme Q10 biosynthesis pathway: cerebellar ataxia and static encephalomyopathy due to COQ5 C-methyltransferase deficiency.

Authors:  May Christine V Malicdan; Thierry Vilboux; Bruria Ben-Zeev; Jennifer Guo; Aviva Eliyahu; Ben Pode-Shakked; Amir Dori; Sravan Kakani; Settara C Chandrasekharappa; Carlos R Ferreira; Natalia Shelestovich; Dina Marek-Yagel; Hadass Pri-Chen; Ilan Blatt; John E Niederhuber; Langping He; Camilo Toro; Robert W Taylor; John Deeken; Tal Yardeni; Douglas C Wallace; William A Gahl; Yair Anikster
Journal:  Hum Mutat       Date:  2017-11-08       Impact factor: 4.878

6.  Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders.

Authors:  Julie Mollet; Irina Giurgea; Dimitri Schlemmer; Gustav Dallner; Dominique Chretien; Agnès Delahodde; Delphine Bacq; Pascale de Lonlay; Arnold Munnich; Agnès Rötig
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

7.  COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement.

Authors:  Francesca Diomedi-Camassei; Silvia Di Giandomenico; Filippo M Santorelli; Gianluca Caridi; Fiorella Piemonte; Giovanni Montini; Gian Marco Ghiggeri; Luisa Murer; Laura Barisoni; Anna Pastore; Andrea Onetti Muda; Maria Luisa Valente; Enrico Bertini; Francesco Emma
Journal:  J Am Soc Nephrol       Date:  2007-09-12       Impact factor: 10.121

8.  Next generation sequence analysis for mitochondrial disorders.

Authors:  Valeria Vasta; Sarah B Ng; Emily H Turner; Jay Shendure; Si Houn Hahn
Journal:  Genome Med       Date:  2009-10-23       Impact factor: 11.117

Review 9.  Disorders of Human Coenzyme Q10 Metabolism: An Overview.

Authors:  Iain Hargreaves; Robert A Heaton; David Mantle
Journal:  Int J Mol Sci       Date:  2020-09-13       Impact factor: 5.923

10.  Simultaneous sequencing of 24 genes associated with steroid-resistant nephrotic syndrome.

Authors:  Hugh J McCarthy; Agnieszka Bierzynska; Matt Wherlock; Milos Ognjanovic; Larissa Kerecuk; Shivaram Hegde; Sally Feather; Rodney D Gilbert; Leah Krischock; Caroline Jones; Manish D Sinha; Nicholas J A Webb; Martin Christian; Margaret M Williams; Stephen Marks; Ania Koziell; Gavin I Welsh; Moin A Saleem
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-24       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.